<DOC>
	<DOCNO>NCT01150890</DOCNO>
	<brief_summary>The study examine safety effectiveness AMG 827 treatment moderate severe Crohn 's disease . Patients randomly receive either AMG 827 placebo ( lookalike liquid n't drug ) neither doctor patient know treatment give .</brief_summary>
	<brief_title>AMG 827 Subjects With Moderate Severe Crohn 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>Diagnosed ileal , ileocolonic , colonic Crohn 's disease minimum 6 month prior initiate Study Product Moderately severely active Crohn 's disease , define CDAI score &gt; 250 &lt; 450 baseline Evidence active inflammation Short bowel syndrome Stricture obstructive symptom within 3 month Bowel surgery within 3 month Ileostomy and/or colostomy Any gastric intestinal pouch Ulcerative colitis Evidence infect abscess Bowel perforation evidence noninflammatory obstruction 6 month Stool positive C. Difficile toxin screen Presence active infection require treatment Serious infection within 8 week Significant concurrent medical condition Pregnant breast feeding Significant Laboratory abnormalities Any antiTNF agent within 2 month Steroid enema within 2 week Tysabri ( natalizumab ) within 1 year Biologic agent ( eg , ustekinumab ) , experimental procedure , live vaccine within 3 month Cyclosporine , mycophenolate mofetil , sirolimus ( rapamycin ) , thalidomide tacrolimus within 2 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Ileal Crohn 's Disease</keyword>
	<keyword>Ileo-colonic Crohn 's Disease</keyword>
	<keyword>Colonic Chron 's Disease</keyword>
</DOC>